P
Paulo M. Hoff
Researcher at University of São Paulo
Publications - 288
Citations - 7232
Paulo M. Hoff is an academic researcher from University of São Paulo. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 42, co-authored 274 publications receiving 5890 citations. Previous affiliations of Paulo M. Hoff include Adma.
Papers
More filters
Journal ArticleDOI
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
J. Randolph Hecht,Yung-Jue Bang,Shukui K. Qin,Hyun Cheol Chung,Jianming Xu,Joon Oh Park,Krzysztof Jeziorski,Yaroslav Shparyk,Paulo M. Hoff,Alberto Sobrero,Pamela Salman,Jin Li,Svetlana A. Protsenko,Zev A. Wainberg,Marc Buyse,Karen Afenjar,Vincent Houe,Agathe Garcia,Tomomi Kaneko,Yingjie Huang,Saba Khan-Wasti,Sergio Santillana,Michael F. Press,Dennis J. Slamon +23 more
TL;DR: Addition of lapatinib to CapeOx did not increase OS in patients with HER2-amplified gastroesophageal adenocarcinoma, and no correlation was observed between HER2 immunohistochemistry status and survival.
Journal ArticleDOI
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M Swain,Sandra M Swain,David Miles,Sung Bae Kim,Young-Hyuck Im,Seock-Ah Im,Vladimir Semiglazov,Eva Ciruelos,Andreas Schneeweiss,Sherene Loi,Estefania Monturus,Emma Clark,Adam Knott,Eleonora Restuccia,Mark C. Benyunes,Javier Cortes,Richy Agajanian,Rizvana Ahmad,Bahriye Aktas,Victor Hugo Alencar,Dino Amadori,Jurandyr Andrade,Fabio Franke,Catia Angiolini,Kenjiro Aogi,Jess Armor,Wichit Arpornwirat,Laura Assersohn,William Audeh,Walter E. Aulitzky,Sergio J Azevedo,Maria Alejandra Bartoli,Norberto Batista Lopez,María Bianconi,Laura Biganzoli,Ruemu E. Birhiray,Marianna Bitina,Ron Blachy,Kimberly L. Blackwell,Rita Blanchard,Paulette Blanchet,Ion Boiangiu,Barbara Bower,Christine Brezden-Masley,Adam Brufsky,Leanne Budde,Priscilla Caguioa,Lourdes Calvo,Mario Campone,Robert R. Carroll,Hugo Castro,Valorie Chan,Veena Charu,Saverio Cinieri,Michael R. Clemens,Emilio Alba Conejo,Eduardo Côrtes,Bruno Coudert,Eduardo Cronemberger,Daniel Cubero,Shaker R. Dakhil,Brooke R. Daniel,Neville Davidson,Maria De Fatima Gaui,Susana De La Cruz,Maria Del Pilar,Gilson Delgado,John Allan Ellerton,Cesar Estuardo,Louis Fehrenbacher,Jean-Marc Ferrero,Patrick J. Flynn,Malgorzata Foszczynska-Kloda,Sandra Franco,Hirofumi Fujii,Chris Gallagher,Teresa Gamucci,Nora Giacomi,Miguel Gil I Gil,Antonio Gonzalez Martin,Vera Gorbunova,Eugeny Gotovkin,Nathan B. Green,Elza Grincuka,Eva-Maria Grischke,Vincent Hansen,Jeffrey Hargis,Maik Hauschild,Roberto Hegg,Carolyn B. Hendricks,Robert Hermann,Paulo M. Hoff,Jun Horiguchi,Javier Hornedo Muguiro,Stefano Iacobelli,Kenichi Inoue,Gustavo Ismael,Yoshinori Itoh,Hiroji Iwata,Davi Jendiroba,Rosa Jochim,Alison Jones,Marianne Just,Andre Kallab,Mark Karwal,Masahiro Kashiwaba,Giraldo Kato,Peter A. Kaufman,Pirkko Kellokumpu-Lehtinen,Andreas Kirsch,Igor Kiselev,Paula Klein,Norio Kohno,Mikhail Kopp,Liljana Kostovska-Maneva,Mauricio Kotliar,Iveta Kudaba,Sherko Kümmel,Katsumasa Kuroi,Juan Lacava,Luciano Latini,Soo-Chin Lee,Mikhail Lichinitser,Christopher Lobo,Christoph Maintz,Jedzada Maneecahvakajorn,Alexander Marmé,Gloria Martinez,Norikazu Masuda,Mario Matwiejuk,Vladimir Merculov,Richard A. Michaelson,Luis Miguel,Hernandez Monroy,Filippo Montemurro,Serafin Morales,Rodrigo Moura,Volkmar Mueller,Clive Mulatero,Kazuhiko Nakagami,Takahiro Nakayama,Jeff Neidhart,An Nguyen,Reiki Nishimura,Haruki Ogata,S O'Reilly,Timothy J. O'Rourke,Douglas Otero Reye,Xuenong Ouyang,Ravi Patel,Taral Patel,Jose Luiz Pedrini,Rodrigo Pereira,Alejandra Perez,Carol Peterson,Tadeusz Pienkowski,Helio Pinczowski,Jonathan Polikoff,Wojciech Polkowski,Paola Edith Price,Sue Prill,Frank Priou,Gunta Purkalne,Seppo Pyrhoenen,Robert Quackenbush,Yoshiaki Rai,Nuria Ribelles,Jungsil Ro,Anne Robinson,Robert Robles,Gladys Rodriguez,L Roman,Shigehira Saji,Pedro Sánchez-Rovira,Nobuaki Sato,Marcus Schmidt,Claudia Schumacher,Frank Senecal,Priyanka Sharma,Zhenzhou Shen,Vadim Shirinkin,Edda Simoncini,Thitiya Sirisinha,Raymond Smith,Joohyuk Sohn,Zeljko Soldic,Tania Soria,Darcy Spicer,Vichien Srimuninnimit,Virote Sriuranpong,Elżbieta Starosławska,Petar Stefanovski,Patrapim Sunpaweravong,Julie Taguchi,Koji Takeda,Gabriel Tellez-Trevilla,Randall Thomas,Christoph Thomssen,Zetina Toache,Yutaka Tokuda,Piotr Tomczak,Celia Tosello,Koichiro Tsugawa,Dennis Tudtud,Takayuki Ueno,Brigitte Van Eyll,Mirta Varela,Nikola Vasev,Damir Vrbanec,Xiaojia Wang,Liwei Wang,Junichiro Watanabe,David Waterhouse,Birgitta Wesenberg,Duncan Wheatley,Zee Wan Wong,Sanjay Yadav,Denise A. Yardley,Tsz-Kok Yau,Winnie Yeo,Cheng Ying,Do Youn Oh +221 more
TL;DR: The end-of-study analysis of CLEOPATRA found progression-free and overall survival were significantly improved in the pertuzumab group compared with the placebo group, and the overall survival rates were also significantly improved.
Journal ArticleDOI
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero,Paulo M. Hoff,Lin Shen,Atsushi Ohtsu,Manish A. Shah,Karen Cheng,Chunyan Song,Haiyan Wu,Jennifer Eng-Wong,Katherine Kim,Yoon-Koo Kang +10 more
TL;DR: Overall survival was not significantly different between treatment groups (median overall survival 17·5 months [95% CI 16·2-19·3] in the pertuzumab group and 14·2 months [12·9-15·5) in the control group), and overall survival did not significantly improve overall survival in the intention-to-treat population.
Journal ArticleDOI
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
Luis Felipe Campesato,Romualdo Barroso-Sousa,Leandro Jimenez,Bruna R. Correa,Jorge Sabbaga,Paulo M. Hoff,Luiz F. L. Reis,Pedro A. F. Galante,Anamaria A. Camargo +8 more
TL;DR: The data reveals that CGPs can be used to estimate mutational load and to predict clinical benefit to PD-1 blockade, with similar accuracy to that reported using WES.
Journal ArticleDOI
Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury
Michael J. Overman,Dipen M. Maru,Chusilp Charnsangavej,Evelyn Loyer,Huamin Wang,Priyanka Pathak,Cathy Eng,Paulo M. Hoff,Jean Nicolas Vauthey,Robert A. Wolff,Scott Kopetz +10 more
TL;DR: Increases in spleen size correlate with increasing grade of hepatic sinusoidal injury and can serve as a simple method for identifying patients at risk for this toxicity.